Advertisements

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Category: press-releasesSource: businesswireindiaOct 27th, 2016

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2016

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases.....»»

Category: press-releasesSource: businesswireindiaMar 20th, 2017

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review.....»»

Category: press-releasesSource: businesswireindiaJan 19th, 2017

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD.....»»

Category: press-releasesSource: businesswireindiaSep 6th, 2016

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Category: press-releasesSource: businesswireindiaJun 5th, 2017

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Category: press-releasesSource: prnewswireJan 4th, 2017

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Category: press-releasesSource: prnewswireJan 4th, 2017

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Category: press-releasesSource: prnewswireJan 4th, 2017

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease.....»»

Category: press-releasesSource: businesswireindiaDec 7th, 2016

Suven Life gets patents in Europe, Israel for neuro-degenerative drug candidate

Suven Life gets patents in Europe, Israel for neuro-degenerative drug candidate.....»»

Category: featuresSource: livemintOct 18th, 2016

Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic Response at Week 12 in Patientswith Active Crohn's Disease

Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic Response at Week 12 in Patientswith Active Crohn's Disease.....»»

Category: press-releasesSource: businesswireindiaOct 16th, 2016

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

Bharat Biotech’s Zika vaccine ready to enter phase-1 trial

Bharat Biotech’s Zika vaccine ready to enter phase-1 trial.....»»

Category: featuresSource: livemintOct 6th, 2016

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003).....»»

Category: press-releasesSource: businesswireindiaSep 8th, 2016